The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
A toolkit for healthcare transition in adolescents with MPN
Adolescents and young patients with MPN experience the same complications of MPN as older adults, including thrombosis, bleeding, and disease transformation. Most young patients do not receive healthcare transition (HCT) support, leading to adverse outcomes such as medical complications, increased emergency department use, and poorer medication adherence. Kucine et al. developed an HCT toolkit comprising an educational checklist for physicians, a transition readiness assessment tool for patients, and consensus statements for clinical practice, published in Pediatric Blood & Cancer.1 The toolkit was developed by an international panel of MPN physicians from France, Germany, Italy, and the USA. Pediatric and adult hematologists with expertise in caring for AYAs with MPNs also participated. Seven virtual panel meetings were held over 14 months.
|
Key learnings1 |
The panel recommended incorporating a checklist of key points for physicians to discuss with AYAs with MPN during multiple visits. The checklist sections covered disease knowledge, disease management, and appointment management. |
The readiness assessment tool assesses patients’ disease knowledge, HCP disease monitoring, and treatment. The tool is recommended for administration every 6 months. |
The panel recommended checking VAF of known mutations and a broader myeloid gene panel when feasible, ultrasound of the liver and spleen at diagnosis, and routine reimaging every 1–3 years. |
Routine bone marrow follow-up evaluations for AYAs with stable clinical and laboratory findings were not recommended. |
Platelet counts alone should not be the basis for starting treatment. Cytoreduction agents were recommended for QoL-affecting symptoms or bleeding risks. |
For improving long-term outcomes, IFN was recommended as a first-line cytoreductive agent, particularly in young patients with JAK2V617F- or CALR-mutated MPN. |
The toolkit represents an initial effort to improve the healthcare transition process for AYAs with MPN. Further research is needed to refine, implement, and evaluate the impact of the toolkit in real-world settings. |
Abbreviations: AYA, adolescent and young adult; CALR, calreticulin; ED, emergency department; HCT, healthcare transition; IFN, interferon; MPN, myeloproliferative neoplasms; QoL, quality of life; VAF, variant allele frequency.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
